The content on this site is intended for healthcare professionals only
Professor Matti Aapro from Genolier, Switzerland, talks to ecancerTV about advances in anaemia management in cancer patients receiving chemotherapy over the past few years. He notes the challenges in managing these patients, and gives an overview of the results of analyses with ESAs in terms of safety, as well as recommendations for their use. He also notes the potential benefits of using iron in selected patients.
Professor Aapro outlines the possible role of blood transfusions in anaemia in oncology, and points to new data presented at ASH 2012 and comments on how these data compare to data presented at ASH 2011. Professor Matti Aapro also summarises the latest data on tumour progression.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
New classification for identifying HR myeloma based on cytogenetic abnormalities
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Use of bispecifics and CAR T cells in South America
Revolutionising myeloma treatment through immune profiling
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
